抗PLA2R1抗体作为膜性肾病预后生物标志物的研究
该队列研究纳入168例PLA2R1相关膜性肾病患者,基线抗PLA2R1抗体滴度与肾病综合征严重程度相关,但在校正蛋白尿和血肌酐后与疾病进展无关。研究质疑单次基线抗体测定的预后价值,建议未来探索序贯监测的作用。
要点
- 基线抗PLA2R1抗体滴度与肾病综合征严重程度相关。
- 校正蛋白尿和血肌酐后,基线抗体滴度与疾病进展无关。
- 单次基线抗PLA2R1抗体测定不宜作为预后生物标志物。
核心结论
- 单次基线抗PLA2R1抗体测定作为膜性肾病预后生物标志物的相关性存疑。
- 未来需研究序贯监测抗PLA2R1抗体对疾病进展的预后价值。
研究设计与样本
- 队列研究,纳入1995年2月至2016年11月转诊至肾内科中心的168例患者(男118例,女50例),平均年龄52±13岁。
- 156例为新发疾病,12例为复发(n=10)或近期使用免疫抑制治疗(n=2)。
- 基线测量抗PLA2R1抗体滴度,主要终点为60个月内进展至严重疾病(血清肌酐增加30%或开始免疫抑制治疗)。
主要发现
- 抗PLA2R1抗体滴度与肾病综合征严重程度存在明确关联。
- 单变量分析中,抗PLA2R1抗体滴度与疾病进展相关。
- 在包含蛋白尿和血清肌酐的Cox比例风险模型中,抗PLA2R1抗体滴度与临床结局不再相关。
- 仅限新发疾病患者分析时结果相似。
临床怎么用
- 不应仅依据单次基线抗PLA2R1抗体滴度预测膜性肾病疾病进展。
- 需结合蛋白尿和血清肌酐等指标综合评估预后。
局限性
- 仅评估基线单次抗PLA2R1抗体测定,未分析序贯监测的价值。
- 样本来自单中心,包含少量复发或近期免疫抑制治疗患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Personalized treatment for patients with membranous nephropathy requires accurate prediction of the disease course at an early stage. In this study, we evaluated the value of baseline anti-phospholipase A2 receptor (PLA2R1) antibody titer as a prognostic biomarker in patients with PLA2R1-associated membranous nephropathy. METHODS: In this cohort study, we included 168 patients (118 men, 50 women) referred to our nephrology center between February 1995 and November 2016. Mean age was 52 ± 13 years. There were 156 patients with new-onset disease and 12 patients with a relapse (n = 10) or recent use of immunosuppressive therapy (n = 2). We measured anti-PLA2R1 titer at baseline and analyzed progression to severe disease (30% increase of serum creatinine or start of immunosuppressive therapy) as a primary study endpoint over 60 months. RESULTS: There was a clear association between anti-PLA2R1 antibody titer and severity of the nephrotic syndrome. In univariate analysis, anti-PLA2R1 antibody titer was also associated with disease progression. However, in Cox proportional hazard models that included proteinuria and serum creatinine, anti-PLA2R1 antibody titer was no longer associated with clinical outcome. Results were similar when limiting the analysis to the patients with new-onset disease. CONCLUSION: Our study questions the relevance of single measurement of anti-PLA2R1 antibodies at baseline as a prognostic biomarker in membranous nephropathy. Future studies are needed to determine the possible role of sequential measurements of anti-PLA2R1 antibodies as a prognostic biomarker of disease progression.
引用
- Logt AV, Justino J, Vink CH, et al. Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy. Kidney Int Rep. 2021. PMID: 34169209. doi:10.1016/j.ekir.2021.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。